GB Patent

GB9308957D0 — Novel produgs

Assigned to Cancer Research Campaign Technology Ltd · Expires 1993-06-16 · 33y expired

What this patent protects

PCT No. PCT/GB94/00941 Sec. 371 Date Dec. 21, 1995 Sec. 102(e) Date Dec. 21, 1995 PCT Filed May 3, 1994 PCT Pub. No. WO94/25429 PCT Pub. Date Nov. 10, 1994The invention provides a compound which is a 3-fluorobenzamide of the formula (A) <IMAGE> (A) wherein R-NH is the …

USPTO Abstract

PCT No. PCT/GB94/00941 Sec. 371 Date Dec. 21, 1995 Sec. 102(e) Date Dec. 21, 1995 PCT Filed May 3, 1994 PCT Pub. No. WO94/25429 PCT Pub. Date Nov. 10, 1994The invention provides a compound which is a 3-fluorobenzamide of the formula (A) <IMAGE> (A) wherein R-NH is the residue of an alpha -amino acid R-NH2 or oligopeptide R-NH2, and M is a nitrogen mustard group of the formula <IMAGE> wherein Y and L, which may be the same or different in a molecule, are leaving groups; or a pharmaceutically acceptable salt thereof. The compounds are useful as prodrugs for treating cancer.

Drugs covered by this patent

Patent Metadata

Patent number
GB9308957D0
Jurisdiction
GB
Classification
—
Expires
1993-06-16
Drug substance claim
No
Drug product claim
No
Assignee
Cancer Research Campaign Technology Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.